Molecular tests, drug testing and specialty labs

Where you are

Specialty laboratory reports can contain many technical terms and results. Your job is to identify the performed assay and the applicable reporting structure. A long report does not prove that the laboratory performed many separately reportable procedures.

This lesson introduces molecular testing, multianalyte assays, drug testing, therapeutic assays, reproductive laboratory work and cytogenetics. Keep the code book open. These sections depend on the exact method, test identity, output and unit, so memory alone is a poor substitute for the complete entry.

Begin with the laboratory's actual assay

Record the test name, specimen source, method, genes or other targets examined, and whether one procedure produces the results together. NCCI includes sample preparation, cell lysis and internal adequacy measures in molecular pathology procedures. Measuring the extracted nucleic acid is also included in the described molecular service. [ncci-laboratory-2026, F.2–3]

DNA and RNA are different molecules, but their appearance together in a report does not automatically create two services. Read whether the applicable entry already includes the combined analysis. Do not separately add preparation steps because they appear as separate lines in the laboratory workflow.

Several targets may belong to one procedure

Genomic sequencing and multianalyte procedures may examine several genes at once. NCCI generally prohibits separately adding another method for the same gene or region already included in the comprehensive procedure. The applicable entries and medical necessity must support any reported combination. [ncci-laboratory-2026, F.5–7]

Original fictional example: a sequencing procedure includes a particular gene, and a second method tests the same region only to verify the result. Do not assume that the second instrument creates a separate service. Identify whether the work merely duplicates the included result or answers a distinct necessary question under an applicable exception.

Sequential testing can have a different relationship. NCCI discusses circumstances where one method does not identify a relevant variant and a further ordered method is necessary. Preserve the sequence, clinical purpose and treating-practitioner order rather than using an automatic modifier for any two methods. [ncci-laboratory-2026, F.7–9]

Unlisted reporting needs the specific instruction

For multiple genes evaluated by one procedure, NCCI directs one unit of the applicable procedure. Its molecular section also addresses situations with no accurate existing entry and describes unlisted or medically necessary component reporting under specified conditions. Read that specific instruction; do not apply a blanket rule that every unlisted molecular assay must be split or can never have component reporting. [ncci-laboratory-2026, F.8]

Record the performed work and why available entries fail to describe it. An unlisted service is not permission to omit the method, order or necessity documentation. Nor should the coder invent a code from the number of genes tested.

MAAA and proprietary assays need exact matching

A multianalyte assay with algorithmic analysis combines measurements with a defined analysis. A proprietary laboratory analysis entry identifies a specific test. NCCI notes that PLA entries describe manufacturers' tests and applies its duplicate-analyte rules to these broader assay families. [ncci-laboratory-2026, A,F.6,N.2]

Use the exact test identity and current entry, including any instructions directing reporting to a named assay. A marketing phrase such as “advanced genomic profile” is not enough. Ask for the laboratory's performed test details when the record lacks them.

For a book exercise, find the MAAA and PLA instructions and record where the applicable test-identification information appears. Explain how you would distinguish a defined assay from a generic collection of individually ordered measurements without copying the proprietary descriptor into this course.

Interpretation is not automatically another service

Medicare permits the specified molecular physician interpretation service only when its conditions are met. These include an attending-physician request, a written narrative and medical judgment that exceeds what a nonphysician laboratory specialist ordinarily supplies. A laboratory scientist's interpretation does not meet the physician requirement. [ncci-laboratory-2026, F.1,M.4]

The unit also depends on the molecular tier, procedure and distinct specimen source. Do not count every sentence of the narrative, every gene result or every slide as an interpretation unit. Trace the applicable rule before counting.

Presumptive and definitive drug tests differ

Presumptive testing supplies an initial drug-testing result using the documented method. Definitive testing identifies drugs or metabolites through the applicable definitive method. Under Medicare NCCI, the presumptive group permits one code per date of service, and the specified definitive HCPCS group likewise permits one code per date. [ncci-laboratory-2026, E.1,M.19–20]

Do not multiply units by the number of positive results, drugs on the medication list or collection cups. Select from the actual performed method and the applicable drug-class instructions. A payer's coverage policy may further govern the necessity and frequency of testing; the unit rule alone does not promise payment.

Specimen-validity measurements used to check for adulteration are included in the drug-testing relationship described by NCCI. Urinary pH or creatinine measured for that purpose does not become a separate diagnostic assay simply because it has a numerical result. [ncci-laboratory-2026, E.2]

A therapeutic assay has a documented purpose

A therapeutic drug assay measures a medication in the setting described by its entry. Do not choose it merely because the patient takes that medication. Distinguish monitoring a prescribed drug concentration from a broader presumptive or definitive drug-testing procedure, then verify the actual ordered assay in the current book.

Write the medication, specimen, method, clinical purpose and performed test. If the record says only “drug level,” obtain enough detail to identify the assay. NCCI's analyte and duplicate-testing principles still apply; changing the label does not establish a second performed test. [ncci-laboratory-2026, A,N.2]

Reproductive laboratory work needs the performed step

Use the reproductive medicine subsection to distinguish the actual laboratory work from collection, clinical evaluation and other treatment phases. A specimen name alone does not tell you the preparation, examination or analysis performed.

Original fictional worksheet: “semen received” documents receipt, while a completed method record describes the actual analysis. The coder needs the latter to compare the full available entries. Record the test, preparation and output; do not construct a service from intended future work. Apply the same rule against counting multiple outputs from one procedure as separate procedures. [ncci-laboratory-2026, A,N.2]

Cytogenetics has study and interpretation units

Cytogenetics examines chromosomes and related abnormalities. NCCI distinguishes the analysis from the applicable interpretation and explains why several cells or karyotypes can be included in one unit. More cells do not automatically mean the same number of procedure units. [ncci-laboratory-2026, M.4–5]

For the cited cytogenetic interpretation service, CMS treats the report as the synthesis of the day's applicable testing rather than a separate unit for every specimen or test. Do not transfer that unit to molecular physician interpretation, which has its own detailed rule. [ncci-laboratory-2026, M.4]

Book drill

Compare one molecular assay with its included preparation, find a named specialty assay and identify the drug-testing unit. Then explain why the cytogenetic interpretation unit cannot be inferred from the number of cells examined.

Checkpoint

Check method, purpose and unit

Use the actual assay, its complete current entry and the applicable payer rule. Preparation and duplicate verification can be included. Presumptive and definitive groups have date-based limits. Specialty interpretation requires its own qualifications and unit review; a long report alone proves neither.

Sources

1. CMS — Medicare NCCI 2026 Chapter X: Pathology and Laboratory. 2026. Accessed 2026-09-10.